Clopidogrel and proton pump inhibitors: Gastric protection at expense of vascular benefit?

Thrombosis and Haemostasis

Volumn 101, Issue 4, 2009, Pages 607-609

  Serebruany, Victor ^a,c   Goto, Shinya ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b TOKAI UNIVERSITY   (Japan)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CLOPIDOGREL; ESOMEPRAZOLE; NITRATE; PANTOPRAZOLE; PROTON PUMP INHIBITOR;

ANTICOAGULANT THERAPY; CLINICAL TRIAL; DRUG ABSORPTION; DRUG EFFECT; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; EDITORIAL; FOOD AND DRUG ADMINISTRATION; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; HEART FAILURE; HEART INFARCTION; HEARTBURN; HUMAN; INTESTINE ULCER; LOW DRUG DOSE; PRIORITY JOURNAL; STOMACH PH; STOMACH PROTECTION; STOMACH ULCER; SUDDEN DEATH; THROMBOSIS; ULCER;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADENOSINE DIPHOSPHATE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; OMEPRAZOLE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROTON PUMP INHIBITORS; STENTS; TICLOPIDINE;

EID: 64849105131     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-02-0077     Document Type: Editorial

References (30)

1. Trifirò G, Corrao S, Alacqua M, et al. Interaction risk with proton pump inhibitors in general practice: significant disagreement between different drug-related information sources. Br J Clin Pharmacol 2006; 62: 582-590.
2. Li, XQ; Andersson, TB, Ahlstrom, M, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004; 32: 821-827.
3. Robinson, M, Horn, J. Clinical pharmacology of proton pump inhibitors: what the practicing physician needs to know. Drugs 2003; 63: 2739-2754.
4. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation. A new drug-drug interaction. Circulation 2003; 107: 32-37.
5. Neubauer H, Günesdogan B, Hanefeld C, et al. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function - a flow cytometry study. Eur Heart J 2003; 24: 1744-1749.
6. Serebruany VL, Midei MG, Malinin AI, et al. Absence of interaction between atorvastatin or other statins and clopidogrel. Results from the INTERACTION study. Arch Intern Med 2004; 164: 2051-2057.
7. Gorchakova O, von Beckerath N, Gawaz M, et al. Antiplatelet effects of a 600mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. Eur Heart J 2004; 25: 1898-1902.
8. Saw J, Steinhubl SR, Berger PB, et al.. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 2003; 108: 921-924.
9. Wienbergen H, Gitt AK, Schiele R, et al. Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. Am J Cardiol 2003; 92: 285-288.
10. Hollopeter G, Jantzen HM, Vincent D, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409: 202-207.
11. Chan FKL, Ching JYL, Hung LCT, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. New Engl J Med 2005; 352: 238-244.
12. Miner P Jr, Katz PO, Chen Y, et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol. 2003; 98: 2616-2620.
13. Hollander D, Dadufalza VD, Fairchild PA. Intestinal absorption of aspirin. Influence of pH, taurocholate, ascorbate, and ethanol. J Lab Clin Med 1981; 98: 591-598.
14. Kambayashi J, Shinoki N, Nakamura T, et al. Prevalence of impaired responsiveness to epinephrine in platelets among Japanese. Thromb Res 1996; 81: 85-90.
15. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. J Am Med Assoc 2006;295: 180-189.
16. Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009; 101: 714-719.
17. Lanas A, García-Rodríguez LA, Arroyo MT, et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol 2007; 102: 507-515.
18. Gellatly RM, Ackman ML. Single antiplatelet therapy for patients with previous gastrointestinal bleeds. Ann Pharmacother 2008; 42: 836-840.
19. Lanas A, Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin 2007; 23: 163-173.
20. Caruana JA, McCabe MN, Smith AD, et al. Risk of massive upper gastrointestinal bleeding in gastric bypass patients taking clopidogrel. Surg Obes Relat Dis 2007; 3: 443-445.
21. Toyoda K, Yasaka M, Iwade K, et al. Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: a prospective, multicenter, observational study. Stroke 2008; 39: 1740-1745.
22. Ng FH, Lam KF, Wong SY, et al. Upper gastrointestinal bleeding in patients with aspirin and clopidogrel co-therapy Digestion 2008; 77: 173-177.
23. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51: 256-260.
24. Siller-Matula JM, Spiel AO, Lang IM, et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009; 157: 148.el-5.
25. FDA. 2007 safety alerts for drugs, biologics, medical devices, and dietary supplements: Omeprazole, omeprazole + sodium bicarbonate. August 9, 2007.http://www.fda.gov/medwatch/safety/2007/ safety07.htm#Omeprazole.
26. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008; 52: 1502-1517.
27. De Miguel A, Ibanez B, Badimón JJ. Clinical implications of clopidogrel resistance. Thromb Haemost 2008; 100: 196-203.
28. Zimmermann N, Hohlfeld T. Clinical implications of aspirin resistance. Thromb Haemost. 2008;100(3):379-90.
29. Neubauer H, Lask S, Engelhardt A, et al. How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification. Thromb Haemost 2008; 99: 357-362.
30. Serebruany V, Pokov I, Kuliczkowski W, et al. Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease. Thromb Haemost 2008; 100: 76-82.